Advertisement

Association of Surgery and Chemotherapy in Stage IV Gastroenteropancreatic Neuroendocrine Carcinoma

  • Author Footnotes
    1 Drs Wong and Dasari contributed equally to the study.
    William G. Wong
    Footnotes
    1 Drs Wong and Dasari contributed equally to the study.
    Affiliations
    Department of Surgery, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania
    Search for articles by this author
  • Author Footnotes
    1 Drs Wong and Dasari contributed equally to the study.
    Arvind Dasari
    Footnotes
    1 Drs Wong and Dasari contributed equally to the study.
    Affiliations
    Division of Cancer Medicine, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Search for articles by this author
  • Chan Shen
    Correspondence
    Corresponding author. Department of Surgery, The Pennsylvania State University, College of Medicine, 500 University Drive, P. O. Box 850, Hershey, PA 17033-0850. Tel.: +717 531-7068.
    Affiliations
    Division of Outcomes Research and Quality, Department of Surgery, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania

    Division of Health Services and Behavioral Research, Department of Public Health Sciences, The Pennsylvania State University, College of Medicine, Hershey, Pennsylvania
    Search for articles by this author
  • Author Footnotes
    1 Drs Wong and Dasari contributed equally to the study.
Published:November 23, 2022DOI:https://doi.org/10.1016/j.jss.2022.10.058

      Abstract

      Introduction

      The survival benefit of chemotherapy for patients with metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) is well established. However, reasons for underutilization of chemotherapy are unknown.

      Methods

      The National Cancer Database (NCDB) was queried for metastatic GEP-NECs from 2009 to 2016. The cohort was stratified by patients who had received chemotherapy and who did not receive chemotherapy. Demographic, socioeconomic, clinical, and treatment characteristics were captured. Multivariable logistic regression examined factors associated with chemotherapy utilization.

      Results

      Of the 2367 stage IV GEP-NECs patients identified, 1647 (69.6%) received chemotherapy. Patients with primary site at colon and small bowel, age ≥75, no insurance, and ≥2 comorbidities were less likely to receive chemotherapy than patients with other primary sites, age <75, private insurance, and no comorbidities (P < 0.005). The small bowel and colon were the primary sites with the greatest percentage of patients who received surgery (46.4% and 41.8%, respectively). In these subgroup of patients, surgical intervention was also associated with lower probability of receiving chemotherapy (odds ratio = 0.60, P < 0.005).

      Conclusions

      About 30% of patients with metastatic GEP-NECs did not receive chemotherapy. Primary site location and receipt of surgery were significantly associated with receipt of chemotherapy, with NECs in small bowel and colon being more likely to receive surgery and less likely to receive chemotherapy. While surgery may be considered on an individual basis, increasing efforts to ensure patients with colon or small bowel NECs receive guideline-concordant chemotherapy will positively impact survival. In addition, interventions to improve health insurance coverage to increase receipt of chemotherapy are warranted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Surgical Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Dasari A.
        • Mehta K.
        • Byers L.A.
        • Sorbye H.
        • Yao J.C.
        Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases.
        Cancer. 2018; 124: 807-815
        • Strosberg J.R.
        • Coppola D.
        • Klimstra D.S.
        • et al.
        The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.
        Pancreas. 2010; 39: 799-800
        • Shah M.
        • Goldner W.
        • Al B.
        • et al.
        Neuroendocrine and Adrenal Tumors National Comprehensive Cancer Network 2.2021, NNCCN clinical practice guidelines in oncology.
        J Natl Compr Canc Netw. 2021; 19: 839-868
        • Sorbye H.
        • Welin S.
        • Langer S.W.
        • et al.
        Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.
        Ann Oncol. 2013; 24: 152-160
        • Garcia-Carbonero R.
        • Sorbye H.
        • Baudin E.
        • et al.
        ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas.
        Neuroendocrinology. 2016; 103: 186-194
        • Boffa D.J.
        • Rosen J.E.
        • Mallin K.
        • et al.
        Using the National Cancer Database for outcomes research: a review.
        JAMA Oncol. 2017; 3: 1722-1728
      1. National cancer database Participant user FIle.
        in: 2017 Data Dictionary. Cancer Programs-American College of Surgeons, Chicago, IL2017: 335
        • Deyo R.A.
        • Cherkin D.C.
        • Ciol M.A.
        Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
        J Clin Epidemiol. 1992; 45: 613-619
        • Tran C.G.
        • Sherman S.K.
        • Howe J.R.
        The Landmark Series: management of small bowel neuroendocrine tumors.
        Ann Surg Oncol. 2021; 28: 2741-2751
        • Obeidat N.A.
        • Pradel F.G.
        • Zuckerman I.H.
        • et al.
        Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer.
        Am J Manag Care. 2010; 16: 515-522
        • Hao Y.
        • Landrine H.
        • Jemal A.
        • et al.
        Race, neighbourhood characteristics and disparities in chemotherapy for colorectal cancer.
        J Epidemiol Community Health. 2011; 65: 211-217
        • Klapheke A.
        • Yap S.A.
        • Pan K.
        • Cress R.D.
        Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer.
        Urol Oncol Semin Original Invest. 2018; 36: 308.e319-308.e325
        • Fields A.C.
        • Lu P.
        • Vierra B.M.
        • et al.
        Survival in patients with high-grade colorectal neuroendocrine carcinomas: the role of surgery and chemotherapy.
        Ann Surg Oncol. 2019; 26: 1127-1133
        • Feo L.
        • Polcino M.
        • Nash G.M.
        Resection of the primary tumor in stage IV colorectal cancer: when is it necessary?.
        Surg Clin North Am. 2017; 97: 657-669
        • Shafqat H.
        • Ali S.
        • Salhab M.
        • Olszewski A.J.
        Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis.
        Dis Colon Rectum. 2015; 58: 294-303
        • Merkow R.P.
        • Bentrem D.J.
        • Mulcahy M.F.
        • et al.
        Effect of postoperative complications on adjuvant chemotherapy use for stage III colon cancer.
        Ann Surg. 2013; 258: 847-853
        • Merkow R.P.
        • Bilimoria K.Y.
        • Tomlinson J.S.
        • et al.
        Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer.
        Ann Surg. 2014; 260: 372-377
        • Institute of Medicine
        Crossing the Quality Chasm: A New Health System for the 21st Century.
        The National Academies Press, Washington DC2001
        • Suh W.N.
        • Kong K.A.
        • Han Y.
        • et al.
        Risk factors associated with treatment refusal in lung cancer.
        Thorac Cancer. 2017; 8: 443-450
        • Duma N.
        • Idossa D.W.
        • Durani U.
        • et al.
        Influence of sociodemographic factors on treatment decisions in non-small-cell lung cancer.
        Clin Lung Cancer. 2020; 21: e115-e129
        • Haas J.S.
        • Goldman L.
        Acutely injured patients with trauma in Massachusetts: differences in care and mortality, by insurance status.
        Am J Public Health. 1994; 84: 1605-1608
        • Marcin J.P.
        • Schembri M.S.
        • He J.
        • Romano P.S.
        A population-based analysis of socioeconomic status and insurance status and their relationship with pediatric trauma hospitalization and mortality rates.
        Am J Public Health. 2003; 93: 461-466
        • Shen C.
        • Dasari A.
        • Gu D.
        • et al.
        Costs of cancer care for elderly patients with neuroendocrine tumors.
        PharmacoEconomics. 2018; 36: 1005-1013
        • Zafar S.Y.
        • Abernethy A.P.
        Financial toxicity, Part I: a new name for a growing problem.
        Oncology (Williston Park). 2013; 27: 80-149
        • van der Zwan J.M.
        • Siesling S.
        • van Velthuysen L.
        • Links T.
        • Walenkamp A.
        • Tesselaar M.
        Extra-pulmonary neuroendocrine carcinomas: a population-based study in The Netherlands.
        Neuroendocrinology. 2018; : 50-59
        • Haugvik S.P.
        • Janson E.T.
        • Österlund P.
        • et al.
        Surgical treatment as a Principle for patients with high-grade pancreatic neuroendocrine carcinoma: a Nordic Multicenter Comparative study.
        Ann Surg Oncol. 2016; 23: 1721-1728
        • Tang L.H.
        • Basturk O.
        • Sue J.J.
        • Klimstra D.S.
        A practical approach to the classification of WHO Grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas.
        Am J Surg Pathol. 2016; 40: 1192-1202